Impact of Weight on Work in Medical Residents

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows medical residents in hospital and university settings to see if overweight and obesity relate to work productivity, work ability, quality of life, and well-being. Participants will be assessed at baseline and after 12 months to observe changes in weight, health, and occupational outcomes. The study also explores whether changes in physical health, mental health, and organizational factors help explain any link between weight loss and work performance. No active treatment is given; data collection focuses on natural changes in weight and lifestyle. Results could inform how weight management supports resident well-being and job performance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female medical residents (physicians in specialty training).
* Actively working in hospital or university healthcare settings at the time of enrollment.
* Willing and able to participate in baseline and 12-month follow-up assessments.
* Provision of written informed consent for study participation and processing of personal data.

Exclusion Criteria:

* Pregnancy at baseline or occurring during the follow-up period.
* Presence of severe clinical conditions that significantly impair work ability or performance, including active cancer treatment, unstable cardiovascular disease, major neurological disorders, or diabetes mellitus.
* Inability or unwillingness to complete study assessments.
* Refusal or withdrawal of informed consent.

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS
  Rome, Rm, Italy Recruiting

Study contacts

• Principal investigator: Ivo Iavicoli, Professor — Fondazione Policlinico Gemelli IRCCS - Roma
• Study coordinator: Ivo Iavicoli, Professor
• Email: Ivo.Iavicoli@unicatt.it
• Phone: 0039 0630155145

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.